The role of European healthcare databases for post-marketing drug effectiveness, safety and value evaluation: where does Italy stand?

G Trifirò, R Gini, F Barone-Adesi, E Beghi, A Cantarutti… - Drug Safety, 2019 - Springer
Enormous progress has been made globally in the use of evidence derived from patients'
clinical information as they access their routine medical care. The value of real-world data …

Nitrogen mustards as alkylating agents: a review on chemistry, mechanism of action and current USFDA status of drugs

GS More, AB Thomas, SS Chitlange… - Anti-Cancer Agents …, 2019 - ingentaconnect.com
Background & Objective: Nitrogen mustard derivatives form one of the major classes of anti-
cancer agents in USFDA approved drugs list. These are polyfunctional alkylating agents …

Effects of an e-Prescribing interface redesign on rates of generic drug prescribing: exploiting default options

S Malhotra, AD Cheriff, JT Gossey… - Journal of the …, 2016 - academic.oup.com
Objective Increasing the use of generic medications could help control medical costs.
However, educational interventions have limited impact on prescriber behavior, and e …

Societal value of generic medicines beyond cost-saving through reduced prices

P Dylst, A Vulto, S Simoens - Expert review of pharmacoeconomics …, 2015 - Taylor & Francis
Objective: This paper aims to provide an overview of the added societal value of generic
medicines beyond their cost-saving potential through reduced prices. In addition, an …

[HTML][HTML] Impact of substitution among generic drugs on persistence and adherence: a retrospective claims data study from 2 local healthcare units in the Lombardy …

GL Colombo, E Agabiti-Rosei, A Margonato… - Atherosclerosis …, 2016 - Elsevier
Background The use of generics, equivalent but less expensive drugs, is an important
opportunity to reduce healthcare expenditure. Methods The purpose of this study was to …

Are generic drugs used in cardiology as effective and safe as their brand-name counterparts? A systematic review and meta-analysis

J Leclerc, M Thibault, J Midiani Gonella, C Beaudoin… - Drugs, 2020 - Springer
Abstract Background Previous systematic reviews (2008; 2016) concluded similarity in
outcomes between brand-name and generic drugs in cardiology, but they included≥ 50 …

Prescribing behavior of general practitioners for generic drugs

B Tuncay, S Pagano, M De Santis… - International Journal of …, 2020 - mdpi.com
The factors influencing General Practitioners'(GPs) prescribing behavior are diverse in terms
of health care policies and regulations, GPs' education and experience, demographic trends …

Improving adherence to treatment and reducing economic costs of hypertension: the role of olmesartan-based treatment

FV Costa - High Blood Pressure & Cardiovascular Prevention, 2017 - Springer
Poor adherence to antihypertensive treatment is the single most important factor of
unsatisfactory blood pressure (BP) control. This review focuses on therapy-related factors …

Generic antiretroviral drugs and HIV care: an economic review

Y Yazdanpanah, M Schwarzinger - Médecine et Maladies Infectieuses, 2016 - Elsevier
The cost of HIV care in European countries is high. Direct medical costs, in France, have
been estimated at 500,000 Euros per patient's lifetime (20,000 Euros/year/patient). Overall …

Methodological considerations for comparison of brand versus generic versus authorized generic adverse event reports in the US Food and Drug Administration …

MM Rahman, Y Alatawi, N Cheng, J Qian… - Clinical drug …, 2017 - Springer
Abstract Background The US Food and Drug Administration Adverse Event Reporting
System (FAERS), a post-marketing safety database, can be used to differentiate brand …